ArticleScientific reports2025
Bone marrow mesenchymal stem cells-derived exosomes protect against β-cell destruction models and kidney injury by suppressing ferroptosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A review of recent advances in exosome-mediated drug delivery for regenerative therapy and immunomodulation.Biomedical engineering online · 2026Review
- Advancing mesenchymal stem cell therapy for kidney diseases in companion animals: from mechanisms to clinical application.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bone marrow mesenchymal stem cell-derived exosomes (BMSC-EXOs) exhibit therapeutic potential in type 1 diabetes mellitus (T1D). In a streptozotocin (STZ)-induced T1D mouse model, BMSC-EXOs reduced hyperglycemia, prevented weight loss, and alleviated early-stage diabetic kidney injury. These protective effects were associated with preserving pancreatic islet structure, restoring β-cell insulin production, and reducing oxidative stress. Mechanistically, BMSC-EXOs inhibited ferroptosis by up-regulating Glutathione peroxidase 4 (GPX4) expression, decreasing lipid peroxidation, and preventing β-cell and kidney damage. These findings indicate that BMSC-EXOs protect against STZ-induced β-cell destruction models and T1D-related complications by inhibiting ferroptosis, presenting a potential therapeutic approach for diabetes management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.